Effects of GLP-1RA Treatment on Long-Term Post-PCI Prognosis in T2DM Patients: A Propensity Score Matching Study.

Purpose: Data on the effect of GLP-1RA treatment on the long-term prognosis of patients with diabetes after percutaneous coronary intervention (PCI) are scant. The purpose of this study was to evaluate the effect of GLP-1RA treatment on the long-term prognosis in T2DM patients after PCI.

Patients And Methods: Data on T2DM patients who underwent PCI from January 2019 to December 2020 were retrospectively analyzed. Clinical data and the use of hypoglycaemic drugs were collected. Patients were divided into 2 groups based on whether they were treated with GLP-1RAs: the control group and the GLP-1RA group. PSM was used to match the control group at a 1:1 ratio. Survival curve and univariate and multivariate Cox regression analyses were used to compare the effects of GLP-1RA treatment on prognosis.

Results: A total of 981 patients were enrolled, and 277 pairs (554 patients) were matched with propensity scores. The balance between two groups improved after PSM (>0.05). Compared with the control group, patients in the GLP-1RA group had lower TC, LDL-C, and HbA1c levels (<0.05). After 24 months of follow-up, a total of 93 patients experienced adverse cardiovascular events. The survival curve revealed that the event-free survival rate in the GLP-1RA group was greater than that in the control group (log rank =0.012). Univariate and multivariate Cox regression analyses revealed that BMI (HR: 1.055, 95% CI=1.007-1.105), HDL-C levels (HR: 0.236, 95% CI=0.095-0.583) and GLP-1RA use (HR: 0.617, 95% CI=0.403-0.943) were independent influencing factors of post-PCI major adverse cardiovascular event (MACE) risk in T2DM patients (<0.05).

Conclusion: GLP-1RA treatment demonstrates cardiovascular benefits in T2DM patients following PCI, effectively reducing the risk of MACE, and enhancing long-term prognosis.